Proteolix Garners $79,000,000 Series C Funding

  • Feed Type
  • Date
    9/8/2008
  • Company Name
    Proteolix
  • Mailing Address
    333 Allerton Avenue South San Francisco, CA 94080
  • Company Description
    Proteolix, Inc. is a biopharmaceutical company dedicated to discovering, developing and marketing pharmaceutical products that target the proteasome and the control of protein turnover in cells. The company’s focus is on the treatment of cancer, inflammatory disease, and autoimmunity.
  • Website
    http://www.proteolix.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $79,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    Proceeds from the financing will primarily support the completion of the company’s ongoing Phase 2 clinical trials of carfilzomib, and the advancement of this anti-cancer therapeutic into Phase 3 clinical trials for the treatment of multiple myeloma. Proteolix will also use the funds to advance candidates in the company’s earlier stage pipeline of proteasome inhibitors.
  • M&A Terms
  • Venture Investor
    Nomura Phase4 Ventures
  • Venture Investor
    Advanced Technology Ventures
  • Venture Investor
    Delphi Ventures
  • Venture Investor
    Latterell Venture Partners
  • Venture Investor
    U.S. Venture Partners
  • Venture Investor
    The Vertical Group

By posting a comment, you agree to our terms and conditions.